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Abstract
Rationale Long-term cannabis and cocaine use has been as-
sociated with impairments in reversal learning. However, how
acute cannabis and cocaine administration affect reversal
learning in humans is not known.
Objective In this study, we aimed to establish the acute effects
of administration of cannabis and cocaine on valence-
dependent reversal learning as a function of DRD2 Taq1A
(rs1800497) and COMT Val108/158Met (rs4680) genotype.
Methods A double-blind placebo-controlled randomized 3-
way crossover design was used. Sixty-one regular poly-drug
users completed a deterministic reversal learning task under
the influence of cocaine, cannabis, and placebo that enabled
assessment of both reward- and punishment-based reversal
learning.
Results Proportion correct on the reversal learning task was
increased by cocaine, but decreased by cannabis. Effects of
cocaine depended on theDRD2 genotype, as increases in pro-
portion correct were seen only in the A1 carriers, and not in
the A2/A2 homozygotes. COMT genotype did not modulate
drug-induced effects on reversal learning.
Conclusions These data indicate that acute administration of
cannabis and cocaine has opposite effects on reversal learning.
The effects of cocaine, but not cannabis, depend on interindi-
vidual genetic differences in the dopamine D2 receptor gene.
Keywords Cocaine . Cannabis . THC . Reversal learning .
COMTVal108/158Met .DRD2Taq1A . Polymorphism .
Individual differences . Human
Introduction
Reversal learning is the ability to flexibly adapt behavior in
response to changing stimulus–outcome contingencies. It is a
cognitive function that is frequently reported to be affected by
drug use. Preclinical research has revealed that cannabis and
cocaine are associated with impaired reversal learning
(Egerton et al. 2005; Sokolic et al. 2011; Wright et al. 2013;
McCracken and Grace 2013; Schoenbaum et al. 2004).
Furthermore, chronic cocaine use in human addicted individ-
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uals has been associated with impaired flexible behavior
(Ersche et al. 2008). Impaired reversal learning is also a di-
mension of impulsivity-related traits. Trait impulsivity, which
includes reversal learning, has been related to enhanced drug
self-administration levels in rodents (Cervantes et al. 2013;
Izquierdo and Jentsch 2012; Dalley et al. 2007). How acute
effects of drugs of abuse causally affect reversal learning in
humans is yet to be established. Especially for cocaine,
acute effects are often fundamentally different from chron-
ic use. Long-term studies often show impairments on cog-
nitive functions, while acute administration most often
yields cognitive enhancing effects (Fillmore et al. 2006;
Garavan et al. 2008; Spronk et al. 2013, 2015). Here, we
examined reversal learning following the acute administra-
tion of cannabis and cocaine, the two most commonly used
illicit drugs in Europe (EMCDDA 2014). We also investi-
gated drug-induced effects on reversal learning as a func-
tion of genetic variants in two common dopaminergic can-
didate genes.
None of the previous studies on cannabis and cocaine
have dissociated between reversal based on unexpected re-
ward versus reversal based on unexpected punishment. This
issue is pertinent, because cannabis and cocaine have been
argued to act by way of modulating dopamine transmission,
which is accompanied by a shift in learning from reward
versus punishment (Maia and Frank 2011). Increases in
striatal dopamine transmission, as elicited by cocaine
(Volkow et al. 1997; Wise 1984), are accompanied by better
reward- versus punishment-based reversal learning (Cools
et al. 2009; see also Frank et al. 2004; Frank and O’Reilly
2006; Bódi et al. 2009). In agreement, cocaine has been
shown to enhance reward-magnitude in rats (Roesch et al.
2007) and thus might cause an overall bias to reward over
punishment-related information. This suggests that cocaine
might increase the impact of unexpected reward on reversal
learning—thus improving reward versus punishment reversal
learning. Cannabis has also been associated with increases in
striatal dopamine release (Bossong et al. 2009); however,
others have not been able to replicate this effect (Stokes
et al. 2009; Barkus et al. 2011). Current evidence has also
suggested that cannabis reduces sensitivity to external rein-
forcing stimuli irrespective of their valence (Lane et al. 2002,
2005), which suggests that the valence of the reinforcer does
not play a role in shaping learning after reversals, but rather
has less of an impact on learning overall.
Individual differences in baseline levels of dopamine
synthesis capacity have been shown to be predictive of
the effects of dopaminergic drugs on reversal learning
(Cools et al. 2009). Accordingly, the effects of cannabis
and cocaine might also depend on individual differences
in baseline levels of dopamine (de Wit 1998). Thus, we
exploited common polymorphisms in dopamine genes to
take into account such interindividual differences.
The A1 allele of the DRD2 Taq1A polymorphism is asso-
ciated with lower D2 receptor density and hence decreased
dopamine D2 receptor signaling (Ritchie and Noble 2003;
Jönsson et al. 1999). Moreover, dopamine D2 receptor func-
tion—whether or not investigated by means of polymor-
phisms or pharmacology—has frequently been reported to
be associated with individual differences in reversal learning
(Lee et al. 2007; Jocham et al. 2009; van der Schaaf et al.
2014) and reinforcement learning in general (Eisenegger
et al. 2014). Variation of the COMT Val108/158Met is asso-
ciated with dopamine turnover in the prefrontal cortex.
Carriers of the COMT Val/Val allele show increased COMT
enzyme activity and, consequently, decreased dopamine
levels in comparison to Met homozygotes (Chen et al. 2004;
Tunbridge et al. 2006). Val homozygotes are thought to ex-
hibit the largest cognitive benefit from dopamine-enhancing
substances such as d-amphetamine and modafinil (Mattay
et al. 2003; Bodenmann et al. 2009; but also see Wardle
et al. 2013a). In addition to the role of these two genotypes
in cognition, bothDRD2 andCOMT genotypes are implicated
in the development of addiction (Blum et al. 1995; Munafò
et al. 2007; Tunbridge et al. 2012) and may therefore be in-
volved in modulating the acute effects of drugs of abuse.
In this study, we investigated the acute effects of cannabis
and cocaine in healthy regular users of these drugs. All par-
ticipants received cocaine, placebo, or cannabis in a placebo-
controlled double-blind crossover study design. A reversal
learning paradigm was employed that is well established to
be sensitive to dopaminergic drug manipulations (Cools et al.
2006, 2009; van der Schaaf et al. 2013, 2014).This paradigm
enabled us to assess (1) whether cannabis and cocaine alter
reward-based vs. punishment-based reversal learning and (2)
if drug-induced effects on reversal learning varies as a func-
tion of genetic variation in two dopaminergic genes (DRD2
Taq1A andCOMTVal108/158Met). In order to investigate the
functional selectivity of the effects to reversal learning, we
also investigated attention switch task (AST) and forward
planning (tower of London: ToL). Functional neuroimaging
has most consistently identified the implication of the prefron-
tal cortex during set-switching (Monsell 2003). Forward plan-
ning implicates the prefrontal cortex and striatal dopamine, as
evidenced by studies with patients with Parkinson’s disease,
characterized primarily by severe striatal dopamine depletion
and psychopharmacological studies using drugs that act pri-
marily on striatal dopamine receptors (Newman et al. 2003;
Ravizza and Carter 2008; Dagher et al. 2001; Owen et al.
1998; Mehta et al. 2003; van Wel et al. 2013).
Cocaine was predicted to enhance reward relative to
punishment-based reversal learning. For cannabis, two hy-
potheses were deemed possible. First, cannabis might improve
reward versus punishment reversal learning as a result of the
dopamine-enhancing effects. Second, cannabis might have a
valence-independent impairing effect on reversal learning,
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consistent with prior observations that cannabis reduces sen-
sitivity to external reinforcing stimuli and impairs other exec-
utive functions (e.g., Spronk et al. 2015). Furthermore, we
hypothesized that these drug effects might vary as a function
of individual genetic differences in theCOMTVal108/158Met
and DRD2 Taq1A polymorphisms.
Methods
Subjects
Sixty-four healthy regular (non-addicted) poly-drug users,
aged 18–40 years were recruited through advertisements on
the Internet, university campuses, and word-of-mouth refer-
rals. A total of 61 subjects remained in the study, because 3
had to be excluded. One withdrew consent after the first test-
ing day, one had a cardiovascular reaction to the blood draw
and study discontinuation was decided by the investigators,
and one did not adhere to the abstinence instructions as con-
firmed by high baseline cannabinoid levels for each testing
day. All subjects reported regular cannabis use (i.e., two or
more times per week) and occasional cocaine use (i.e., more
than five times in the previous year). They had to be in good
physical health and be of normal weight (bodymass index 18–
28). Subjects who used other psychotropic medication, report-
ed excessive drinking (>20 standard drinks per week) or
smoking (>20 cigarettes per day) were excluded. Further ex-
clusion criteria were alcohol or substance dependence or his-
tory of psychiatric or neurological disorders as assessed dur-
ing a clinical interview (M.I.N.I. plus; Sheehan et al. 1998),
pregnancy or lactation, and cardiovascular abnormalities as
measured by ECG and hypertension. Not all subjects complet-
ed all tasks in all three drug conditions. Of the 61, 3 subjects
did not complete the attention switch task and 5 did not com-
plete the tower of London in the cannabis drug condition
(because of adverse events). Eight additional datasets of the
tower of London could not be analyzed due to experimenter
error (1 cocaine, 1 placebo) or to non-compliance or failure to
understand the task by the subject as reflected in an overall
performance of less than 60 % correct (3 cannabis, 2 placebo,
1 cocaine). There were 14 missing datasets for the reversal
learning due to adverse events or lack of motivation (13 can-
nabis, 1 cocaine). Data for 4 additional datasets were excluded
due to poor behavioral performance (overall average accuracy
<60 %; 2 cannabis, 1 placebo, 1 cocaine).
The study was part of a multicenter trial, but the current
results were collected at one study site. The reversal learning
task, attention switch task, and the tower of London were
administered as part of a larger cognitive test battery (see
Dutch Trial Register, trial number NTR2127; results will be
published elsewhere). The study was conducted according to
the code of ethics on human experimentation established by
the Declaration of Helsinki (1964, amended in Seoul 2008),
and was approved by the Medical Ethics Committee of
Maastricht University and the regional ethics committee for
the University Medical Center of the Radboud University. A
permit for obtaining, storing, and administering cocaine and
cannabis was obtained from the Dutch Drug Enforcement
Administration.
Procedure
Prior to starting the testing days, all participants were
invited for a screening and practice day where they gave
informed consent and received a medical examination in-
cluding assessment of blood and urine samples for stan-
dard chemistry and hematology, electrocardiogram
(ECG), and interview of medical and drug use history.
All subjects completed shortened versions of all cognitive
paradigms in a practice session.
After study inclusion, subjects completed a series of cog-
nitive tests on three separate testing days that were separated
by at least a week. Subjects were asked to abstain from caf-
feine and nicotine on the testing day and from cannabis and
alcohol at least 24 h prior to each testing day. Figure 1 shows
the timeline of procedures on a testing day. The testing day
started with a light breakfast (non-caffeinated tea or water, up
to four sandwiches) and performance of a urine drug screen,
pregnancy test (women only), and alcohol breath analyzer.
This was followed by pre-drug (baseline) vital sign record-
ings, subjective questionnaires, and blood draws (see
supplementary material 1 for drug metabolites and see van
Wel et al. 2015, for questionnaire data). Subjects received a
capsule containing either 300 mg cocaine HCl or placebo
orally (T0), and 45 min later, subjects inhaled 300 μg/kg can-
nabis or placebo (T1); because the experiment was double-
blind, therefore, all participants had to take a capsule and
complete inhalation. The delay of 45 min was based on prior
observations that the capsule needs about 45 min before plas-
ma concentrations start to increase (Fillmore et al. 2002; and
for a review Bigelow and Walsh 1998). Conversely, cannabis
was anticipated to be absorbed immediately (Grotenhermen
2003). After T1, the first block of behavioral tasks was
assessed (block 1) during which the attention switch task
and tower of London were completed. About 1 h after T1, a
second booster dose of cocaine (150 mg) or placebo followed
by a second dose of cannabis 150 μg/kg or placebo was given
(T2). Next, the second block (block 2) of behavioral tasks was
administered. The reversal learning task was at the end of this
second block. Vital sign recordings, subjective questionnaires,
and blood draws were obtained 5 min after drug administra-
tion (T1 and T2) and at the end of the testing day. An extra
vital sign recording was performed before T2 to assess the
safety of administering the potential booster.
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Of the 59 subjects who completed the reversal learning task
in the cocaine condition, 16 did not receive the second booster
capsule. Five subjects did not receive a second cocaine dos-
age, because the decision to include a second booster dosage
was made after the start of the study and approval for this
amendment had to be awaited. Eleven subjects’ vital signs
exceeded limits for safe administration of the booster.
Supplementary analyses of the effects of cocaine after exclu-
sion of these 16 subjects revealed a similar pattern of the
results. Of the 46 subjects who completed the reversal learning
task in the cannabis condition, 6 did not receive a second
administration (3 refused, 3 exceeded vital sign limits).
Design, study drugs, and administration
This study used a double-blind, double-dummy, placebo-con-
trolled, three-way crossover design. The three possible condi-
tions were as follows: (1) cocaine (placebo cannabis vapor/
cocaine capsules), (2) cannabis (cannabis vapors/placebo co-
caine capsules), and (3) placebo (placebo cannabis vapors/
placebo cocaine capsules). Cannabis was obtained from
flowers of Cannabis sativa, grown according to good
manufacturing practice (GMP)-compliant procedures
(FarmalyseBV, Zaandam, The Netherlands). A herbal mixture
containing hemp flowers was used as placebo for cannabis.
Cannabis was administered in two subsequent dosages that
were tailored to each individual’s weight (T1=300 μg/kg,
T2=150 μg/kg). Cannabis and cannabis placebo were vapor-
ized at a temperature of 225 °C by means of a Volcano®
vaporizer (Storz-Bickel GmbH, Tüttlingen, Germany) 5 min
before administration. The vapor was stored in a polythene
bag equipped with a valved mouthpiece. Subjects were
instructed to inhale deeply, to hold their breath for 10 s after
each inhalation and to take as much time as needed to empty
the bag in order to minimize the occurrence of adverse events.
Cocaine HCl and matching placebo cocaine were encapsulat-
ed in white opaque capsules. The placebo capsules contained
only filling material of equivalent weight. The cocaine HCl
and placebo cocaine were purchased from Mallinckrodt
Pharmaceuticals, St. Louis, MO, USA, and encapsulated and
tested byBasic PharmaGeleen, The Netherlands, according to
Good Manufacturing Practices. Two subsequent dosages of
cocaine capsules (T0=300 mg, T2=150 mg) or placebo cap-
sules were administered. The capsules were taken orally with
150 ml of water. The sequence of the drug conditions was
counterbalanced.
Genetics
Blood samples were obtained by venipuncture, and DNAwas
isolated using the following standard protocols. Molecular
analyses were performed in a certified laboratory at the
Department of Human Genetics, Radboud University
Medical Center, the Netherlands. The DRD2 rs1800497 and
COMT rs4680 polymorphisms were genotyped using
TaqMan-based analysis. Genotyping was performed in a vol-
ume of 10 μl containing 10 ng of genomic DNA. For DRD2,
5 μl of TaqManMastermix (2x; Applied Biosystems,
Nieuwerkerk aan de IJssel, the Netherlands), 0.125 μl of
TaqMan assay (TaqMan assay: C_7486676_10, reporter 1,
VIC-A-allele, reverse assay; Applied Biosystems), and
3.875 μl of water were added. For COMT, 5 μl of ABgene
Mastermix (2x, Applied Biosystems), 0.125 μl of TaqMan
assay (TaqMan assay: C_25746809_50, reporter 1, VIC-A-
allele; Applied Biosystems), and 3.875 μl of water were
added. Amplification was performed on a commercially avail-
able system (7500 Fast Real-Time PCR, Applied
Biosystems), starting with 15 min at 95 °C, followed by 50
cycles of 15 s at 95 °C and 1 min at 60 °C. Genotypes were
scored using the algorithm and software supplied by the man-
ufacturer (Applied Biosystems). To investigate the random
genotyping error rate in the two assays, the laboratory includ-
ed 5 % duplicate DNA samples, which showed 100 % con-
sistency in genotype. There are three genotypes of the dopa-
mine DRD2 Taq1A gene; the A2/A2 variant, the A1/A2 var-
iant, and the A1/A1 variant. The A1/A1 and A1/A2 variants
were grouped together and named the BA1 carriers,^ because
the prevalence of the A1/A1 variant is very low. There are
three variants for the COMT gene; the Val/Val variant, the
Val/Met variant, and the Met/Met variant. The COMT geno-
type could not be determined for two subjects. The observed
distribution of both genotypes was in agreement with expect-
ed values according to the Hardy–Weinberg equilibrium
(pDRD2=0.61; pCOMT=0.13).
Fig. 1 Timeline (in minutes) of
the course of a testing day. The
black triangles represent the
moment of cocaine (or placebo)
capsule administration and the
gray triangles represent the
moment of cannabis (or placebo)
vapor administration. AST
attention switch task, ToL tower
of London, RL reversal learning
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Tasks
Reversal learning
A deterministic reversal learning paradigm was used (see
Fig. 2 and Cools et al. 2006), in which subjects were simulta-
neously presented with a face and scene picture on a trial by
trial basis (location randomized). One of these stimuli was
associated with reward and the other with punishment.
Subjects were instructed to learn these deterministic stimu-
lus–outcome associations by predicting the outcome of the
stimulus that was highlighted by a black border. Outcome
predictions were made by pressing either a red (for punish-
ment) or green (for reward) button with the index finger of the
left and the right hand (counterbalanced between subjects).
Note that the computer selected which stimulus was highlight-
ed and that the outcome was always independent of the sub-
ject’s actual response. One second after the button press, the
outcome was presented for 500 ms at the location of the stim-
ulus. Reward consisted of a green smiley with a B+€100^ sign.
Punishment consisted of a red angry smiley and a B−€100^
sign. Subjects did not get any monetary rewards. The task was
self-paced and no response deadlines were employed. After
4–6 consecutive correct predictions, the stimulus–outcome
contingency reversed. This was signaled by either an unex-
pected reward, presented after the previously punished stimu-
lus was highlighted, or an unexpected punishment, presented
after the previously rewarded stimulus was highlighted. After
unexpected outcomes, the same stimulus was highlighted
again, such that behavioral and cognitive requirements were
matched between valence conditions.
Each participant performed four experimental blocks that
contained 120 trials: two blocks in which reversals were sig-
naled by unexpected rewards (reward valence) and two blocks
in which reversals were signaled by unexpected punishment
(punishment valence). Each block consisted of one acquisition
stage until the first reversal and a variable number of reversal
stages, depending on the participant’s accuracy. Accuracy on
the trials directly following these unexpected outcomes
(switch trials) represents howwell subjects updated their stim-
ulus–outcome associations. The remainder of the trials
consisted of non-switch trials in which subjects simply had
to predict if the trial was associated with reward (non-switch
reward) or punishment (non-switch punishment). Thus, in to-
tal, there were three trial types (switch, non-switch reward,
non-switch punishment) across two valence levels (reward,
punishment). Proportion correct is the main outcome measure
in this task. On the Bscreening and practice day^ subjects
performed two practice blocks to familiarize them with the
paradigm.
Attention switch task
The experimental attention switch task (AST) was used to
measure the subject’s ability to frequently switch attention
between different task instructions (Markus and Jonkman
2007). This task is an adjusted version of the task reported
by Kramer et al. (2001). The AST consists of two non-switch
blocks and one switch block. During the task, four stimulus
types were randomly presented on the screen (1, 3, 111, or
333). During the first non-switch block, the subject was asked
to respond to the question Bwhat number?^ by pressing a left
Fig 2 The deterministic reversal learning task. a An example of a
punishment trial. On each trial, subjects are presented with a face and a
landscape. One of the images is surrounded by a black border. The
subject had to predict whether the surrounded stimulus was followed by
a reward or by a punishment outcome by pressing the associated
Breward^ or Bpunishment^ button on a keyboard. After the response
had been made, the subject saw the actual outcome. b Example of a
trial sequence for the unexpected punishment and unexpected reward
condition. The reversals are indicated by an unexpected reward or
unexpected punishment trial. rw reward prediction, pn punishment
prediction, ns-r non-switch reward trial, ns-p non-switch punishment
trial, sw-r reversal trial after an unexpected reward, sw-p reversal trial
after an unexpected punishment
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button when the cue B1^ or B111^ appeared and a right button
when B3^ or B333^ appeared. In the second non-switch block,
the question Bhowmany?^ had to be answered by pressing the
left button when the cue B1^ or B3^ appeared and the right
button when the cue B111^ or B333^ appeared. In the switch
block, the Bwhat number?^ and Bhow many?^ trials were
randomly intermixed. The non-switch blocks included 40
randomly presented trials each, consisting of 10 stimuli of
each stimulus type. The switch block included 80 ran-
domly presented trials and 20 stimuli of each stimulus
type. The questions were presented for 400 ms, after
which a stimulus was presented for 800 ms. After this, a
2000-ms response interval occurred before the next in-
struction appeared. The dependent variables were mean
proportion correct and reaction time.
Tower of London
The tower of London task provides a measure of forward
planning (Shallice 1982). The original version of the Tower
of London consists of three colored balls, which must be ar-
ranged on three sticks to match the target configuration on a
picture while only one ball can be moved at a time. The pres-
ent version consisted of computer-generated images of begin-
and end-arrangements of the balls. The subjects were asked to
decide as quickly as possible, by pushing a coded button,
whether the end arrangement could be accomplished in 2, 3,
4, 5, or 6 steps from the begin arrangement (Veale et al. 1996).
The complexity of the task was dependent on the minimal
number of steps in which the rearrangement could be
achieved. To avoid guessing, only the trials of two to five steps
are analyzed. Proportion of correct decisions and mean reac-
tion time per step were the main outcome measures.
Data analysis
Potential genotype differences in gender, age, and education
were analyzed through Pearson’s chi-square test or univariate
ANOVA, as appropriate. To assess drug effects on reversal
learning, a linear-mixed model (LMM) was constructed with
subject as a random factor and drugs (cocaine, placebo, can-
nabis); valence (reward, punishment); and trial type (switch,
non-switch reward, non-switch punishment) as fixed factors
in each of the analyses. To assess whether drug effects on
reversal learning depended on individual differences in
COMT or DRD2 genotype, an additional LMM was per-
formed with COMT (Val/Val, Val/Met, Met/Met) and DRD2
(A2/A2, A1 carriers), as two additional fixed factors. To mea-
sure drug effects on AST and ToL performance, LMMs were
constructed with subject as a random factor and drugs (co-
caine, placebo, cannabis); block (switch, non-switch, for
AST); or step (steps 2, 3, 4, and 5, for ToL) as fixed factors.
All individual datasets which involved more than 40 %
overall error rate were excluded as performance was consid-
ered to be at chance level, signaling non-compliance or failure
to understand the instructions. As is appropriate for propor-
tional data, where the variance is proportional to the mean, we
applied arcsine transformation (2x(arcsine(√x)) on all analyses
on proportion correct (Howell 1997). We present and plot raw
data in tables and figures for illustrative purposes. A signifi-
cant interaction effect was followed by drug–placebo contrasts
to establish the separate effects of cannabis and cocaine and
their interaction with genotype. Mixed model analysis of var-
iance rather than ANOVA was chosen because subjects for
whom data were unavailable for one or two of the three drug
conditions could be included in the analysis by assuming
values were missing at random.
Results
Demographics
Table 1 shows the subject characteristics for gender, age, ed-
ucation and drug use history stratified for genotype. There was
a significant DRD2 genotype effect on occasions of cocaine
use in the past year. The A1 carriers showed a higher preva-
lence of cocaine use compared with the A2/A2 homozygotes.
However, the A1 carrier group contained one outlier. There
was no significant DRD2 genotype effect on occasions of
cocaine use when this subject was removed from the analyses
(p=0.17). There were no other significant genotype effects.
Reversal learning
The average proportions of correct responses are shown in
Table 2. Mixed model analysis revealed a significant main
effect of drugs (F2,929.565=76.2, p<0.001), a significant effect
of valence (F1,911.998=5.0, p=0.026), and a significant trial
type × valence interaction (F2, 911.998=67.20, p=0.001).
There was no trial type × drugs interaction (F2, 911.998=
0.0.68, p=0.61), suggesting that drug effects were the same
for switch and non-switch trials. Moreover, in contrast to our
hypothesis, there was no drugs × valence interaction, indicat-
ing that drug effects did not vary as a function of the valence
of the outcome that signaled the need for reversal.
Furthermore, there was also no three-way trial type ×
valence × drugs interaction (p’s>0.99). The main effect
of drugs was due to a higher accuracy after cocaine com-
pared with placebo (M=0.94 vs. 0.91 p<0.001), but lower
accuracy after cannabis compared with placebo (M=0.87
vs. 0.90, p<0.001). Thus, cocaine improved, while can-
nabis impaired performance on the reversal learning task
in a non-valence specific manner and the effects extended
to the non-switch trials.
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Post-hoc analyses of the two-way interaction between va-
lence and trial types showed a significant effect of valence for
switch trials, i.e., across all drug sessions subjects performed
better when unexpected reversal was signaled by punishment
rather than reward (M=0.90 vs. 0.86, p<0.001). No differ-
ences were observed between reward and punishment on the
two types of non-switch trials (p>0.75).
Genetic effects on reversal learning
In addition, we assessed whether reversal learning perfor-
mance was modulated by DRD2 or COMT genotype. The
proportion of correct responses as a function of drug, trial
type, and DRD2 genotype (A2/A2 and A1 carriers) are pre-
sented in Fig. 3. There was a significant DRD2 × drugs inter-
action (F2,841.511=5.33, p=0.005). Follow-up analyses inves-
tigating this DRD2 × drugs interaction for only the cocaine
and placebo datasets demonstrated that the cocaine-induced
improvement was greater in the A1 carriers compared with the
A2/A2 group (F1,589.251=11.9, p=0.001). The DRD2 × drugs
interaction analysis for cannabis and placebo conditions re-
vealed no significant effect (F1,546.422=0.77, p=0.38), sug-
gesting that the effects of cannabis did not differ between
A1 carriers and the A2/A2 group. There were no other signif-
icant interactions with DRD2 genotype (all p’s>0.52). There
was no significant main effect for COMT genotype (p=0.08),
neither were there any significant interactions betweenCOMT
and any of the other factors (all p’s>0.34).
Attention switch task
The average proportion of correct responses and reaction
times for the attention switch and the tower of London tasks
are shown in Table 3. Analysis revealed the expected switch
effect as indicated by a decreased proportion of correct in the
switch compared with the non-switch block (0.97 vs. 0.94; F1,
294.289=117.9 p<0.001). There was also a main effect of drugs
on proportion correct (F2, 295.572=16.9, p<0.001). Pairwise
comparisons revealed that subjects made more errors under
the influence of cannabis compared with placebo (0.94 vs.
0.96, p<0.001). There were no differences between the co-
caine and placebo condition (0.96 vs. 0.96, p=0.26). The
switch × drugs interaction was not significant (F2, 294.289=
2.36, p=0.097), suggesting that the switch effect on propor-
tion correct was not different across the three drugs conditions.
In addition, in terms of reaction times, there was also a main
Table 1 Demographics of subjects stratified per genotype, values are mean±SD
DRD2 genotype COMT genotype
Measure A2/A2 A1 carriers p value MetMet ValMet ValVal p value
N 44 17 23 23 13
Gender (M/F) 36/8 13/4 0.64 16/7 19/4 13/0 0.08
Age (years) 22.1±3.8 23.8±5.3 0.17 23.1±4.8 22.1±3.0 23.1±5.4 0.71
Years of educationa 14.2±2.2 15.0±1.8 0.20 14.6±2.2 14.6±1.9 14.1±2.5 0.80
Occasions of cocaine use (occasions per last year)b 8.9±4.7 15.2±18.1 0.04* 9.2±4.7 9.5±6.3 16.0±20.0 0.13
Estimated frequency of cannabis use (J/W) 5.5±4.9 8.0±5.3 0.078 6.6±4.8 6.4±5.9 5.5±4.7 0.83
a Data is missing for one subject
bWhen one outlying participant was removed, the DRD2 genotype effect on occasions of cocaine use was no longer significant (p=0.17)
Table 2 Behavioral data on the reversal learning task (mean proportion correct±SD)
Cocaine Placebo Cannabis
A2/A2 A1 car A2/A2 A1 car A2/A2 A1 car
(N=42) (N=17) (N=42) (N=17) (N=33) (N=13)
Unexpected reward Switch 0.91±0.091 0.92±0.087 0.88±0.11 0.84±0.10 0.83±0.15 0.77±0.19
Non-switch reward 0.95±0.061 0.95±0.039 0.92±0.074 0.91±0.038 0.90±0.080 0.85±0.12
Non-switch punishment 0.95±0.049 0.94±0.070 0.92±0.089 0.90±0.060 0.91±0.059 0.86±0.094
Unexpected Punishment Switch 0.96±0.045 0.95±0.051 0.92±0.088 0.87±0.11 0.85±0.17 0.84±0.14
Non-switch reward 0.95±0.050 0.95±0.034 0.93±0.044 0.91±0.056 0.89±0.079 0.86±0.10
Non-switch punishment 0. 95±0.051 0.96±0.044 0.93±0.051 0.90±0.054 0.90±0.069 0.88±0.047
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effect of switch (F1, 294.047=241.9, p<0.001) and of drugs (F2,
294.863=13.3, p<0.001). Subjects took longer to respond to
trials in the switch compared with the non-switch block (652
vs. 485 ms). The significant main effect of drugs was due to
overall longer reaction times in the cannabis compared with
placebo condition (603 vs 568 ms, p=0.031) and faster reac-
tion times in the cocaine compared with the placebo condition
(534 vs 568 ms, p=0.028). There was no significant switch ×
drugs interaction (F2, 294.047=0.036, p=0.96), suggesting that
the switch effect on reaction time was not different between
the drugs.
Tower of London
The analyses on the reaction times in the ToL showed the
expected decrease in proportion correct with increasing num-
ber of steps (F3,607.373=104.3, p<0.001). With the exception
of steps 2 and 3, significantly fewer correct responses were
made with each subsequent step (all p’s<0.001). There was
also a significant effect of drugs (F2,619.725=12.1, p<0.001).
Pairwise comparisons revealed that the effect of drugs was
due to an overall lower proportion correct after cannabis com-
pared with placebo (p<0.001), while there were no differences
between placebo and cocaine (p=1.0). The drugs × steps in-
teraction on proportion correct was not significant (F6,619.132=
1.0, p=0.42). Likewise, there was a significant main effect of
steps on reaction time (F3,608.498=560.2, p<0.001), indicating
that reaction time increased with each subsequent step (all p’s
<0.001). In addition, a main effect of drugs (F2,612.612=15.7,
p<0.001) indicated that reaction times were longer after can-
nabis compared with placebo (p<0.001), while there were no
reaction time differences between cocaine and placebo (p=
1.0). There was no interaction between steps × drugs (F6,
608.498=0.76, p=0.61).
Discussion
The main findings of this study are that (1) cocaine and can-
nabis exerted opposite effects on reversal learning that are
Fig. 3 Proportion correct for the
cocaine, placebo, and cannabis
conditions as a function of DRD2
Taq1A genotype collapsed across
the different trial types (mean±
SEM)
Table 3 Behavioral data on
attention switch task (AST) and
tower of London (ToL) after pla-
cebo, cocaine, and cannabis
(mean±SD)
Placebo Cocaine Cannabis
Attention switch task
Non-switch RT (ms) 483±91 452±67 517±142
proportion correct 0.98±0.026 0.98±0.024 0.96±0.036
Switch RT (ms) 654±198 617±148 682±201
proportion correct 0.95±0.050 0.95±0.036 0.92±0.049
Tower of London
2 steps RT (s) 4962±1404 4910±1690 6161±2625
proportion correct 0.94±0.088 0.95±0.090 0.92±0.12
3 steps RT (s) 6218±1870 6292±2513 7377±2740
proportion correct 0.95±0.071 0.95±0.068 0.92±0.093
4 steps RT (s) 9449±3452 9144±3184 10,914±3909
proportion correct 0.88±0.10 0.85±0.11 0.82±0.15
5 steps RT (s) 15,337±4839 15,278±4988 15,760±5904
proportion correct 0.76±0.18 0.79±0.17 0.69±0.17
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non-specific with respect to valence. Cocaine increased pro-
portion correct whereas cannabis decreased proportion cor-
rect. These effects were observed across all trials: switch and
non-switch; (2) drug effects on reversal learning did not vary
with the valence of the outcome (reward vs. punishment) sig-
naling the need for reversal; and (3) the DRD2 Taq1A geno-
type differentially modulated the effects of cocaine, but not
cannabis. Specifically, the results suggested that cocaine im-
proved performance to a greater degree in the A1 carriers
compared with the A2/A2 genotype group. The COMT
Val108/158Met did not affect reversal learning.
Cocaine induced a larger improvement in the DRD2 A1
allele carriers compared with the A2/A2 homozygotes.
Furthermore, this was irrespective of switch or non-switch
trials, suggesting that this effect reflects modulation of rein-
forcement learning rather than reversal learning specifically.
The finding that cocaine had greater beneficial effects in sub-
jects with genetically determined lower dopamine D2 receptor
density concurs with prior pharmacogenetic studies also
showing greater effects of dopaminergic drugs in such sub-
jects (Cohen et al. 2007; Kirsch et al. 2006; Pearson-Fuhrhop
et al. 2013; Kwak et al. 2013). For example, in the work by
Cohen et al. (2007) it was shown that administration of the
dopamine D2 receptor agonist cabergoline resulted in stronger
task-related neural activation in the A1 carriers compared with
the A2/A2 genotype group. The results also accord with a
recent pharmacological PET study in healthy individuals
(Ersche et al. 2011), which demonstrated that the beneficial
effects of the dopamine receptor agonist pramipexole on rever-
sal learning depended on baseline levels of dopamine D2/3 re-
ceptor availability in the striatum (Ersche et al. 2011). Although
cocaine is pharmacologically different from the dopamine pre-
cursor L-dopa and the dopamine receptor agonists investigated
in the aforementioned studies (Cohen et al. 2007; Kirsch et al.
2006; Pearson-Fuhrhop et al. 2013; Kwak et al. 2013), these
studies generally concur to suggest that the degree of cognitive
benefit after increasing dopamine transmission is predicted by
baseline dopamine D2 receptor availability.
The DRD2 Taq1A polymorphism did not explain interin-
dividual differences in the effects of cannabis. To the authors’
knowledge there are currently no published cannabis drug
studies that investigate the interaction with the DRD2 Taq1A
genotype. Cannabis has a unique and complicated pharmaco-
logical profile, involving many neurotransmission systems
such as dopamine, GABA, and acetylcholine (Bossong et al.
2009; Stokes et al. 2009; Barkus et al. 2011; Wilson and
Nicoll 2002). It is likely that cannabis’ effects on cognition
are predominantly mediated by neurotransmitters other than
dopamine. More extensive future studies should address the
pharmacogenetic effects of cannabis on cognition.
Whether individual differences in acute drug effects on
reversal learning could provide information with relevance
for drug-using individuals is an intriguing question. Our
results showed that the A1 carriers showed the largest cogni-
tive benefits after cocaine. Assuming that cognitive benefits
from a drug are a direct motivational reinforcer for use, co-
caine’s beneficial effect on reversal learning could further re-
veal a potential mechanism by which the A1 carriers are more
vulnerable for cocaine use. The higher benefit from cocaine
for A1 carriers perhaps means that the reinforcing effects are
larger for this group. This fits well with studies showing that
lowered expression of D2 receptors is associated with stronger
pleasurable responses to stimulants (Volkow et al. 1999;
Spellicy et al. 2014) and research showing that the A1 allele
of the DRD2 Taq1A genotype is associated with greater pro-
pensity for drug use and addiction (Persico et al. 1996; Bühler
et al. 2015).
In contrast to the DRD2 Taq1A gene, the COMT Val108/
158Met genotype did not interact with drug effects. This lack of
significant association might be due to a lack of statistical pow-
er, which is a common problem in gene-cognition studies.
While an effect of COMT on cognition has been demonstrated
many times (Tunbridge et al. 2006), it can often not be repli-
cated (Barnett et al. 2008; Wardle et al. 2013b). This includes
failures to replicate seminal pharmacogenetic findings on
which our hypotheses were based (Mattay et al. 2003). The
current results thus suggest that better powered studies are
needed to establish the role of the COMT gene in cognition in
general and in combination with pharmacological substances.
Irrespective of the DRD2 genotype interaction with drugs,
it is notable that the impaired learning in the DRD2 A1 allele
carriers comparedwith the A2/A2 group agrees with a number
of studies (Jocham et al. 2009; Klein et al. 2007; Richter et al.
2014). Specifically, these studies indicated that carriers of the
gene variant associated with presumably lower D2 receptor
density show impaired performance on reinforcement learning
(Klein et al. 2007; Frank et al. 2007), as well as impaired
avoidance learning (Richter et al. 2014). This also concurs
with prior observations from pharmacological work showing
that reversal learning performance depends on the degree of
dopamine D2 receptor availability (van der Schaaf et al. 2013;
Groman et al. 2011). However, our finding of impaired learn-
ing in the A1 allele carriers compared with the A2/A2 was
irrespective of valence. This contrasts with studies that have
linked theDRD2 polymorphisms to learning from punishment
or avoidance learning specifically (Frank and Hutchison 2009;
Klein et al. 2007; Frank et al. 2007). However, we note that
the paradigms used in the various studies are very different:
where we employed a deterministic paradigm in which the
outcome was dependent on the stimulus, previous work com-
monly used a probabilistic reversal learning paradigm in
which the outcome was dependent on the response.
Cocaine is a powerful stimulant and the observed improve-
ment on the reversal learning task is in the same direction as
the effects of other stimulant drugs such as amphetamine and
modafinil on learning tasks in humans (Pessiglione et al.
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2006; Wickens 1990; Pringle et al. 2013). Stimulant drugs
share comparable pharmacological properties such as increas-
ing dopamine and noradrenaline levels in the brain and en-
hancement of arousal (Kuczenski and Segal 1994; Berridge
2006). These results support the interpretation that cocaine
facilitates overall learning due to its stimulant properties. By
contrast, the cocaine-induced performance improvement con-
trasts with previous observations in rodents and humans
showing that prior chronic use of cocaine is associated with
impaired reversal learning (Ersche et al. 2008; Jentsch et al.
2002; Schoenbaum et al. 2004; Calu et al. 2007; McCracken
and Grace 2013). As such, the present results concur with
previous findings showing that acute effects of cocaine can
be opposite to the chronic effects of cocaine (reviewed in
Spronk et al. 2013). Moreover, this cocaine-induced improve-
ment in learning was restricted to the reversal learning task
and did not extend to the other tasks. Performance on the
attentional switch task and tower of London were unaffected
by cocaine, although reaction times on the AST were faster
after cocaine. Other studies on stimulant drugs have also failed
to show effects on forward planning and switching of attention
(vanWel et al. 2013; Hermens et al. 2007; Linssen et al. 2012;
but also see Elliott et al. 1997; Rogers et al. 1999). This sug-
gests that cocaine enhances the more cognitive demanding
process of reversal learning, but leaves basal functions such
as attention switching and forward planning intact.
Additionally, we observed that valence differentially affect-
ed learning. Participants seemed to learn better after punish-
ment rather than reward predicting reversal. Most relevant to
the current investigation, drugs did not differentially affect the
degree of learning from reward versus punishment, but instead
only revealed a general improvement on all trial types. For
cocaine, the results contrasted with our hypothesis in which
we expected relative enhanced improvement in reward versus
punishment learning. These results are in striking contrast with
previous findings showing opposite effects of dopaminergic
agents on reward and punishment learning (Cools et al. 2006;
Frank and O’Reilly 2006; Cools et al. 2009; van der Schaaf
et al. 2013) even when using the same task (Cools et al. 2006,
van der Schaaf et al. 2013). On the other hand, they seem to
concur with recent pharmacological studies showing unidirec-
tional effects on both reward and punishment learning
(Pessiglione et al. 2006, Jocham et al. 2014). There are several
reasons that may explain these contrasting results.
One possible explanation may relate to the instrumental
and Pavlovian learning components in our reversal learning
task (Van der Schaaf et al. 2013). Subjects could improve on
the task by detecting whether the outcome, which solely de-
pends on the stimulus and not on subjects’ actions, is better or
worse than expected. This process depends on learned
(Pavlovian) stimulus–outcome associations and is measured
by the accuracy on the trials directly after a reversal signaled
by unexpected rewards and unexpected punishments.
Alternatively, subjects could improve on the task by detecting
whether their action was correct or incorrect by means of a
match or mismatch between their prediction (action) and the
outcome. This process depends on instrumental (action-
outcome) associations and may be reflected by general accu-
racy on all trials (irrespective of outcome valence or reversal).
Indeed, in previous studies, an instrumental learning task
(without reversals) was used in which improvement in both
reward-approach as well as punishment-avoid learning was
observed (Pessiglione et al. 2006; Jocham et al. 2014).
Taken together, our findings that cocaine improved general
accuracy might reflect improvements on the instrumental
component of our task, which could have overshadowed the
(expected) valence-dependent effects.
Alternatively, the lack of valence-specific effects after co-
caine may imply enhanced saliency of both reward and punish-
ment signals. Dopamine has been shown to code information
related to salient events (Bromberg-Martin et al. 2010; Horvitz
2000) and can predict both reward- and punishment-related
information (Matsumoto and Hikosaka 2009; Brischoux et al.
2009). Accordingly, enhanced motivational salience due to el-
evated dopamine levels could thus have led to equally im-
proved learning from both reward and punishment signals.
Third, cocaine is different from the (mostly) agonists and an-
tagonists that were administered in previous work and might
therefore exert very different effects. Cocaine does not only
enhance dopaminergic neurotransmission, but affects the sero-
tonergic and noradrenergic systems as well (Ritz et al. 1990).
Therefore, not only the elevated dopamine levels, but also other
cathecholamines might be responsible for non-specific alter-
ations in learning (Breitenstein et al. 2006; Mitchell et al.
2007). In other words, the general pharmacological effects of
cocaine may have resulted in more general changes on our task
by affecting multiple learning components of the tasks (e.g.,
saliency or instrumental learning processes), while more spe-
cific pharmacological agents like D2 receptor (ant)agonists
used in previous studies may have more specific effects.
In contrast to cocaine, cannabis yielded an overall impair-
ment in reversal learning task which was valence-independent.
Furthermore, the cannabis-induced impairments were across
switch and non-switch trials. We have also found impaired per-
formance on the attention switch task and tower of London. The
results also occur with studies cannabis administration studies
on other executive functions like response inhibition and error
monitoring, which show comparable impairments (Spronk et al.
2015; van Wel et al. 2013; Kowal et al. 2015). Our results
suggest that cannabis affects a generic process, rather than
exerting any specific effects on cognitive functions.
Diminished motivation, or decreased willingness to exert effort,
is a well-known side effect of cannabis use (Lynskey and Hall
2000). The results from the current study thus suggest that di-
minished motivation might underlie impaired performance un-
der acute influence as well.
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A number of issues could have influenced the interpreta-
tion of our results. First, it is possible that ceiling effects oc-
curred in the cocaine condition. This is of particular relevance
for the interpretation of the DRD2 genotype interaction. The
A2/A2 group might, for example, have shown a further
cocaine-induced performance increase if the task would have
been more difficult. However, the number of participants that
reached the maximum score was low, with only a minor dif-
ference between the A1 carriers and the A2/A2 group.
Second, we used a statistical model (linear-mixed model) that
assumes that missing values were missing at random. Most of
the missing cases, however, were in the cannabis condition.
The extent to which the missing cases were actually random
could be questioned, as they were often subjects who were the
most tired/least motivated to continue testing. However, we
already found an impaired performance under cannabis. If
anything, inclusion of those subjects would have demonstrat-
ed an even stronger impairment on the level of condition.
Third, all subjects reported the use of other substances (most
notably XTC, amphetamine, alcohol, and nicotine). The re-
quired abstinence, of smoking in particular, could have
yielded underperformance in each of the conditions.
However, as this effect would have been the same in each of
the three conditions, it is unlikely that this had a large effect on
the outcomes. Ideally, future studies should address how co-
caine and cannabis affect reversal learning in naive users, but
ethical concerns limit the feasibility of such studies. Fourth,
differences in pharmacodynamics and fatigue effects might
have contributed to the dissociative effects on the AST and
ToL versus the reversal learning task. The AST and ToL were
assessed early in the testing day after the first drug adminis-
tration, while the reversal learning task was assessed at the
very end of the testing day after the second drug administra-
tion. Fifth, although our study is the largest of its kind, the
power to detect effects of genotype is limited. For the COMT
gene, genotype data was available for only 59 subjects, with a
particularly small Val/Val group (N=13).
In conclusion, this study has demonstrated that acute ad-
ministration of cannabis and cocaine result in opposing effects
on reversal learning and that cocaine’s effects on reversal
learning are dependent on individual genetic differences in
the dopamine D2 receptor gene.
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